a Totally Synthetic, Self-Assembling, Adjuvant-Free MUC1 Glycopeptide Vaccine for Cancer Therapy-Reference-Cited by-同舟云学术

a Totally Synthetic, Self-Assembling, Adjuvant-Free MUC1 Glycopeptide Vaccine for Cancer Therapy

Published:2012-05-17 Issue:21 Volume:134 Page:8730-8733
ISSN:0002-7863
Container-title:Journal of the American Chemical Society
language:en
Short-container-title:J. Am. Chem. Soc.

Author:

Huang Zhi-Hua¹,Shi Lei¹,Ma Jing-Wen¹,Sun Zhan-Yi¹,Cai Hui¹,Chen Yong-Xiang¹,Zhao Yu-Fen¹,Li Yan-Mei¹

Affiliation:

1. Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Colloid and Surface Chemistry,Biochemistry,General Chemistry,Catalysis

Link

https://pubs.acs.org/doi/pdf/10.1021/ja211725s

Reference28 articles.

1. Synthetic Glycopeptides from the Mucin Family as Potential Tools in Cancer Immunotherapy

2. Synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates and Their Evaluation as Vaccines

3. Synthetic Vaccines Consisting of Tumor-Associated MUC1 Glycopeptide Antigens and Bovine Serum Albumin

4. From Synthesis to Biologics: Preclinical Data on a Chemistry Derived Anticancer Vaccine

5. The Immunogenicity of the Tumor-Associated Antigen Lewisy May Be Suppressed by a Bifunctional Cross-Linker Required for Coupling to a Carrier Protein

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apoptotic cell mimics enhance immunogenic cell death and inflame tumor microenvironment by modulating macrophages;Nano Today;2024-10

2. Shark anti-idiotypic variable new antigen receptor specific for an alpaca nanobody: Exploration of a nontoxic substitute to ochratoxin A in immunoassay;Journal of Hazardous Materials;2024-09

3. Theranostic applications of peptide-based nanoformulations for growth factor defective cancers;International Journal of Biological Macromolecules;2024-03

4. Myeloid Cell‐Triggered In Situ Cell Engineering for Robust Vaccine‐Based Cancer Treatment;Advanced Materials;2024-02-06

5. Synthetic self‐adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy;MedComm;2024-02